DRW Securities’s Ovid Therapeutics OVID Stock Holding History

DRW Securities’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18,317	Closed	-$143K	–	84
2018 Q2	$143K	Buy	18,317 +3,000	+20%	+$25.8K	0.01%	80
2018 Q1	$108K	Buy	+15,317	New	+$124K	0.01%	144

Other funds holding OVID

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

DRW Securities's OVID Position: Q3 2018 in Review

DRW Securities sold out of Ovid Therapeutics (OVID) in Q3 2018, closing a stake of 18,317 shares — an estimated $143K sold.

DRW Securities first reported a position in OVID in Q1 2018 and held it in 2 quarters. The position peaked at $143K in Q2 2018. 49 funds tracked by Wall St. Rank hold OVID as of Q3 2018.

DRW Securities reported no remaining Ovid Therapeutics position as of Q3 2018 after selling out during the quarter.
DRW Securities sold 18,317 Ovid Therapeutics shares in Q3 2018, an estimated $143K.
DRW Securities first reported a position in Ovid Therapeutics in Q1 2018 and held it in 2 quarters.
DRW Securities's Ovid Therapeutics position peaked at $143K in Q2 2018.
49 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.